Clinical Trials Directory

Trials / Completed

CompletedNCT02242955

Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
26 (actual)
Sponsor
University Hospital, Lille · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Alcohol-dependence is a medical condition that can lead to the occurrence of an alcohol withdrawal syndrome (AWS) in case of alcohol drinking cessation. Diazepam is the reference medication for preventing or treating AWS. The recommended average diazepam treatment duration is usually around one week, and this duration is generally not considered to impact the subsequent relapse rate in alcohol drinking. However, several previous studies have found that patients experienced frequent anxious symptoms during the weeks following detoxification. Such symptoms may foster early relapse in alcohol drinking. Furthermore, it has been suggested that this anxiety could pertain to late withdrawal symptoms. The DIAMA study hypothesizes that extending the diazepam detoxification treatment to one month can significantly reduce the cumulated relapse rate in alcohol drinking over the three following months.

Detailed description

* inclusion at Day 5 of the outpatient alcohol detoxification procedure * randomization in two arms: 1) "10 day - diazepam"; and 2) "30 day - diazepam" * tapering of diazepam over the 10 days following the beginning of the detoxification procedure in the first arm; tapering of diazepam over the 30 days following the beginning of the detoxification procedure in the second arm. * 3-month-long follow-up after detoxification. Objective of maintaining abstinence from alcohol. No use of additional anticraving drug. Standardised psychotherapeutic support based on the BRENDA model. * Longitudinal recording of alcohol consumption using the Alcohol Timeline Follow-Back method. * Assessment of craving (Obsessive-Compulsive Drinking Scale) and anxiety (State-Trait Anxiety Inventory; Hamilton Anxiety Rating Scale) at Days 5 (baseline), 15, 30, 60 and 90 (final assessment).

Conditions

Interventions

TypeNameDescription
DRUGDiazepam40 mg per day.

Timeline

Start date
2014-07-01
Primary completion
2016-07-01
Completion
2016-07-01
First posted
2014-09-17
Last updated
2016-09-15

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT02242955. Inclusion in this directory is not an endorsement.